Streetbeat News

Analyst Ratings

FCX

Morgan Stanley analyst Carlos De Alba has maintained an Equal-Weight rating on Freeport-McMoRan (NYSE:FCX) and lowered the price target from $44 to $41.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:12 pm

FITB

Morgan Stanley analyst Manan Gosalia maintains an Equal-Weight rating on Fifth Third Bancorp (NASDAQ:FITB) and raises the price target from $28 to $29.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:11 pm

EFX

Morgan Stanley analyst Toni Kaplan has maintained an Equal-Weight rating on Equifax (NYSE:EFX) and lowered the price target from $204 to $196.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:09 pm

NVST

Morgan Stanley analyst Drew Ranieri has maintained an Overweight rating on Envista Holdings (NYSE:NVST) but lowered the price target from $46 to $42.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:07 pm

DFS

Morgan Stanley analyst Betsy Graseck has maintained an Equal-Weight rating on Discover Financial Services (NYSE:DFS) but lowered the price target from $100 to $95.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:04 pm

PFE

UBS analyst Colin Bristow has assumed Pfizer (NYSE:PFE) with a Neutral rating and lowered the price target to $34.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:02 pm

XRAY

Morgan Stanley analyst Erin Wright has maintained an Overweight rating on Dentsply Sirona (NASDAQ:XRAY) but lowered the price target from $47 to $43.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:02 pm

AMRC

Over the past 3 months, 7 analysts have published their opinion on Ameresco (NYSE:AMRC) stock. The company has an average price target of $59.14, representing a 7.35% decrease from the previous average price target of $63.83. The majority of the analysts are bullish on the stock.

Portfolio Pulse from Benzinga Insights

October 20, 2023 | 12:01 pm

GMED

Analysts have provided various ratings for Globus Medical (NYSE:GMED) within the last quarter, with 2 bullish, 2 somewhat bullish, and 4 indifferent. The average 12-month price target for the company is $68.75, a decrease of 0.07% from the previous average price target of $68.80.

Portfolio Pulse from Benzinga Insights

October 20, 2023 | 12:01 pm

ENOV

Over the past 3 months, 4 analysts have given their opinion on Enovis (NYSE:ENOV) stock. The majority of these ratings have been bullish, with an average 12-month price target of $71.25, which has increased by 6.34% over the past month.

Portfolio Pulse from Benzinga Insights

October 20, 2023 | 12:00 pm